Back to IONS
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
2 competitors in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
View Full LandscapeDrug Information
Target Indication
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Clinical Trial
NCT04136171Last updated: 12/4/2025
Patent & Exclusivity
ActiveRLD
Latest Patent Expiry
Aug 25, 2034(7y 12m)
Patents Listed
4
Exclusivity
NCEODE-461
Application
NDA 217388Regulatory Approvals
EMA3/6/2025
Wainzua
Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts